氟西汀 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "氟西汀" in Chinese language version.

refsWebsite

Global rank Chinese rank

64nih.gov

4^th place

5^th place

57doi.org

2^nd place

23^rd place

40web.archive.org

1^st place

18semanticscholar.org

11^th place

332^nd place

6fda.gov

447^th place

581^st place

5harvard.edu

18^th place

57^th place

4books.google.com

3^rd place

8^th place

3drugs.com

399^th place

208^th place

2worldcat.org

5^th place

12^th place

2faa.gov

1,009^th place

2,216^th place

2caa.co.uk

5,211^th place

4,443^rd place

2tga.gov.au

3,984^th place

1,603^rd place

1canada.ca

1,712^th place

3,316^th place

1in.gov.br

3,151^st place

low place

1lillychina.com

low place

1google.ca

838^th place

259^th place

1who.int

195^th place

179^th place

1msh.org

low place

2,351^st place

1modernmedicine.com

low place

1psychcentral.com

9,619^th place

low place

1ahrq.gov

9,469^th place

9,001^st place

1nihr.ac.uk

low place

1wfsbp.org

low place

1plosjournals.org

low place

5,715^th place

1exlibrisgroup.com

9,042^nd place

low place

1mhra.gov.uk

low place

1uptodate.com

3,771^st place

4,225^th place

1popsci.com

2,941^st place

2,593^rd place

1answers.com

1,580^th place

2,207^th place

1lilly.com

low place

1archive.org

6^th place

4^th place

1indystar.com

1,646^th place

6,186^th place

1express-scripts.com

low place

1bbc.co.uk

8^th place

32^nd place

1washingtonpost.com

34^th place

129^th place

1archive.today

14^th place

18^th place

1veterinaryevidence.org

low place

ahrq.gov

effectivehealthcare.ahrq.gov

Forman-Hoffman V, Middleton JC, Feltner C, Gaynes BN, Weber RP, Bann C, Viswanathan M, Lohr KN, Baker C, Green J. Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update (报告). Comparative Effectiveness Review. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ). 2018-05-17 [2024-02-12]. doi:10.23970/ahrqepccer207. （原始内容存档于2018-07-10）. |issue=被忽略 (帮助)

answers.com

wiki.answers.com

Can you get high on fluoxetine?. [2011-08-29]. （原始内容存档于2011-11-23）（英语）.

archive.org

Wong, DT, Bymaster FP, Engleman EA. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci. 1995, 57 (5): 411–41. PMID 7623609. doi:10.1016/0024-3205(95)00209-O.

archive.today

MacPherson M. Prozac, Prejudice and the Politics of Depression. The Washington Post. 1990-09-02 [2018-04-23]. （原始内容存档于2021-09-03）.

bbc.co.uk

Macnair P. BBC – Health: Prozac. BBC. September 2012. （原始内容存档于2012-12-11）. In 2011 over 43 million prescriptions for antidepressants were handed out in the UK and about 14 percent (or nearly 6 million prescriptions) of these were for a drug called fluoxetine, better known as Prozac.

books.google.com

Hubbard JR, Martin PR. Substance Abuse in the Mentally and Physically Disabled. CRC Press. 2001: 26. ISBN 978-0-8247-4497-7.
Hagerman RJ. Angelman Syndrome and Prader-Willi Syndrome. Neurodevelopmental Disorders: Diagnosis and Treatment. Oxford University Press. 1999-09-16. ISBN 978-0-19-512314-2. Dech and Budow (1991) were among the first to report the anecdotal use of fluoxetine in a case of PWS to control behavior problems, appetite, and trichotillomania.
Janicak PG, Marder SR, Pavuluri MN. Principles and Practice of Psychopharmacotherapy. Lippincott Williams & Wilkins. 26 December 2011. ISBN 978-1-4511-7877-7. A 2-week interval is adequate for all of these drugs, with the exception of fluoxetine. Because of the extended half-life of norfluoxetine, a minimum of 5 weeks should lapse between stopping fluoxetine (20mg/day) and starting an MAOI. With higher daily doses, the interval should be longer.
Janicak PG, Marder SR, Pavuluri MN. Principles and Practice of Psychopharmacotherapy. Lippincott Williams & Wilkins. 26 December 2011-12-26. ISBN 978-1-4511-7877-7. A 2-week interval is adequate for all of these drugs, with the exception of fluoxetine. Because of the extended half-life of norfluoxetine, a minimum of 5 weeks should lapse between stopping fluoxetine (20mg/day) and starting an MAOI. With higher daily doses, the interval should be longer. 请检查|date=中的日期值 (帮助)

caa.co.uk

Mental Health GM - Centrally Acting Medication. Civil Aviation Authority. [2021-07-21].
Class 1/2 Certification – Depression (PDF). Civil Aviation Authority. [2021-07-21]. （原始内容 (PDF)存档于2021-10-10）.

canada.ca

Mental health. Health Canada. 9 May 2018 [2024-04-13]. （原始内容存档于2024-09-21）.

doi.org

Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clinical Pharmacokinetics. March 1994, 26 (3): 201–14. PMID 8194283. S2CID 1406955. doi:10.2165/00003088-199426030-00004.
Forman-Hoffman V, Middleton JC, Feltner C, Gaynes BN, Weber RP, Bann C, Viswanathan M, Lohr KN, Baker C, Green J. Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update (报告). Comparative Effectiveness Review. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ). 2018-05-17 [2024-02-12]. doi:10.23970/ahrqepccer207. （原始内容存档于2018-07-10）. |issue=被忽略 (帮助)
Husted DS, Shapira NA, Murphy TK, Mann GD, Ward HE, Goodman WK. Effect of comorbid tics on a clinically meaningful response to 8-week open-label trial of fluoxetine in obsessive compulsive disorder. Journal of Psychiatric Research. 2007, 41 (3–4): 332–337. PMID 16860338. doi:10.1016/j.jpsychires.2006.05.007.
Williams K, Brignell A, Randall M, Silove N, Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). The Cochrane Database of Systematic Reviews. August 2013, 8 (8): CD004677. PMC 11990048 . PMID 23959778. doi:10.1002/14651858.CD004677.pub3.
Myers SM. The status of pharmacotherapy for autism spectrum disorders. Expert Opinion on Pharmacotherapy. August 2007, 8 (11): 1579–1603. PMID 17685878. S2CID 24674542. doi:10.1517/14656566.8.11.1579.
Doyle CA, McDougle CJ. Pharmacotherapy to control behavioral symptoms in children with autism. Expert Opinion on Pharmacotherapy. August 2012, 13 (11): 1615–1629. PMID 22550944. S2CID 32144885. doi:10.1517/14656566.2012.674110.
Benvenuto A, Battan B, Porfirio MC, Curatolo P. Pharmacotherapy of autism spectrum disorders. Brain & Development. February 2013, 35 (2): 119–127. PMID 22541665. S2CID 19614718. doi:10.1016/j.braindev.2012.03.015.
Mahdi M, Hermán L, Réthelyi JM, Bálint BL. Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19. International Journal of Molecular Sciences. March 2022, 23 (7): 3812. PMC 8998734 . PMID 35409171. doi:10.3390/ijms23073812 .
Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JP, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JP, Geddes JR. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. April 2018, 391 (10128): 1357–1366. PMC 5889788 . PMID 29477251. doi:10.1016/S0140-6736(17)32802-7.
Magni LR, Purgato M, Gastaldon C, Papola D, Furukawa TA, Cipriani A, Barbui C. Fluoxetine versus other types of pharmacotherapy for depression. The Cochrane Database of Systematic Reviews. July 2013, 2013 (7): CD004185. PMC 11513554 . PMID 24353997. doi:10.1002/14651858.CD004185.pub3.
Antidepressants for children and teenagers: what works for anxiety and depression?. NIHR Evidence (Plain English summary) (National Institute for Health and Care Research). 3 November 2022 [2025-05-08]. S2CID 253347210. doi:10.3310/nihrevidence_53342. （原始内容存档于2022-11-05）.
Boaden K, Tomlinson A, Cortese S, Cipriani A. Antidepressants in Children and Adolescents: Meta-Review of Efficacy, Tolerability and Suicidality in Acute Treatment. Frontiers in Psychiatry. 2 September 2020, 11: 717. PMC 7493620 . PMID 32982805. doi:10.3389/fpsyt.2020.00717 .
Correll CU, Cortese S, Croatto G, Monaco F, Krinitski D, Arrondo G, Ostinelli EG, Zangani C, Fornaro M, Estradé A, Fusar-Poli P, Carvalho AF, Solmi M. Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. World Psychiatry. June 2021, 20 (2): 244–275. PMC 8129843 . PMID 34002501. doi:10.1002/wps.20881.
Aigner M, Treasure J, Kaye W, Kasper S. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders (PDF). The World Journal of Biological Psychiatry. September 2011, 12 (6): 400–43. PMID 21961502. S2CID 16733060. doi:10.3109/15622975.2011.602720. （原始内容存档 (PDF)于2014-08-01）.
Rapkin AJ, Lewis EI. Treatment of premenstrual dysphoric disorder. Women's Health. November 2013, 9 (6): 537–56. PMID 24161307. doi:10.2217/whe.13.62 .
Carr RR, Ensom MH. Fluoxetine in the treatment of premenstrual dysphoric disorder. The Annals of Pharmacotherapy. April 2002, 36 (4): 713–7. PMID 11918525. S2CID 37088388. doi:10.1345/aph.1A265.
Romano S, Judge R, Dillon J, Shuler C, Sundell K. The role of fluoxetine in the treatment of premenstrual dysphoric disorder. Clinical Therapeutics. April 1999, 21 (4): 615–33; discussion 613. PMID 10363729. doi:10.1016/S0149-2918(00)88315-0.
Pearlstein T, Yonkers KA. Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder. Expert Opinion on Pharmacotherapy. July 2002, 3 (7): 979–91. PMID 12083997. S2CID 9455962. doi:10.1517/14656566.3.7.979.
Cohen LS, Miner C, Brown EW, Freeman E, Halbreich U, Sundell K, McCray S. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstetrics and Gynecology. September 2002, 100 (3): 435–44. PMID 12220761. S2CID 753100. doi:10.1016/S0029-7844(02)02166-X.
Coccaro EF, Lee RJ, Kavoussi RJ. A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder. The Journal of Clinical Psychiatry. April 2009, 70 (5): 653–62. PMID 19389333. doi:10.4088/JCP.08m04150.
Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Archives of General Psychiatry. December 1997, 54 (12): 1081–8. PMID 9400343. doi:10.1001/archpsyc.1997.01830240035005.
George DT, Phillips MJ, Lifshitz M, Lionetti TA, Spero DE, Ghassemzedeh N, Doty L, Umhau JC, Rawlings RR. Fluoxetine treatment of alcoholic perpetrators of domestic violence: a 12-week, double-blind, randomized, placebo-controlled intervention study. The Journal of Clinical Psychiatry. January 2011, 72 (1): 60–5. PMC 3026856 . PMID 20673556. doi:10.4088/JCP.09m05256gry.
Serralde-Zúñiga AE, Gonzalez Garay AG, Rodríguez-Carmona Y, Melendez G. Fluoxetine for adults who are overweight or obese. The Cochrane Database of Systematic Reviews. October 2019, 10 (10): CD011688. PMC 6792438 . PMID 31613390. doi:10.1002/14651858.CD011688.pub2. 已忽略未知参数|collaboration= (帮助)
Taurines R, Gerlach M, Warnke A, Thome J, Wewetzer C. Pharmacotherapy in depressed children and adolescents. The World Journal of Biological Psychiatry. September 2011, 12 (Suppl 1): 11–5. PMID 21905988. S2CID 18186328. doi:10.3109/15622975.2011.600295.
Cohen D. Should the use of selective serotonin reuptake inhibitors in child and adolescent depression be banned?. Psychotherapy and Psychosomatics. 2007, 76 (1): 5–14. PMID 17170559. S2CID 1112192. doi:10.1159/000096360.
Rowe T. Drugs in Pregnancy. Journal of Obstetrics and Gynaecology Canada. June 2015, 37 (6): 489–92. PMID 26334601. doi:10.1016/S1701-2163(15)30222-X .
David Healy, Andrew Herxheimer, and David B. Menkes. Antidepressants and Violence: Problems at the Interface of Medicine and Law. PLoS Med. 2006, (3(9): e372) [2020-09-12]. doi:10.1371/journal.pmed.0030372. （原始内容存档于2009-03-20）.
Bhat V, Kennedy SH. Recognition and management of antidepressant discontinuation syndrome. Journal of Psychiatry & Neuroscience. June 2017, 42 (4): E7–E8. PMC 5487275 . PMID 28639936. doi:10.1503/jpn.170022.
Gabriel M, Sharma V. Antidepressant discontinuation syndrome. CMAJ. May 2017, 189 (21): E747. PMC 5449237 . PMID 28554948. doi:10.1503/cmaj.160991.
Sørensen A, Juhl Jørgensen K, Munkholm K. Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review. Therapeutic Advances in Psychopharmacology. 2022, 12: 20451253211067656. PMID 35173954. doi:10.1177/20451253211067656.
Ross LE, Grigoriadis S, Mamisashvili L, Vonderporten EH, Roerecke M, Rehm J, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry. April 2013, 70 (4): 436–43. PMID 23446732. doi:10.1001/jamapsychiatry.2013.684 .
Lattimore KA, Donn SM, Kaciroti N, Kemper AR, Neal CR, Vazquez DM. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. Journal of Perinatology. September 2005, 25 (9): 595–604. PMID 16015372. S2CID 5558834. doi:10.1038/sj.jp.7211352.
Gao SY, Wu QJ, Sun C, Zhang TN, Shen ZQ, Liu CX, Gong TT, Xu X, Ji C, Huang DH, Chang Q, Zhao YH. Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births. BMC Medicine. November 2018, 16 (1): 205. PMC 6231277 . PMID 30415641. doi:10.1186/s12916-018-1193-5 .
De Vries C, Gadzhanova S, Sykes MJ, Ward M, Roughead E. A Systematic Review and Meta-Analysis Considering the Risk for Congenital Heart Defects of Antidepressant Classes and Individual Antidepressants. Drug Safety. March 2021, 44 (3): 291–312 [2025-05-08]. PMID 33354752. S2CID 229357583. doi:10.1007/s40264-020-01027-x. （原始内容存档于2023-03-07）.
Gao SY, Wu QJ, Zhang TN, Shen ZQ, Liu CX, Xu X, Ji C, Zhao YH. Fluoxetine and congenital malformations: a systematic review and meta-analysis of cohort studies. British Journal of Clinical Pharmacology. October 2017, 83 (10): 2134–2147. PMC 5595931 . PMID 28513059. doi:10.1111/bcp.13321.
Leslie LK, Newman TB, Chesney PJ, Perrin JM. The Food and Drug Administration's deliberations on antidepressant use in pediatric patients. Pediatrics. July 2005, 116 (1): 195–204. PMC 1550709 . PMID 15995053. doi:10.1542/peds.2005-0074.
Fornaro M, Anastasia A, Valchera A, Carano A, Orsolini L, Vellante F, Rapini G, Olivieri L, Di Natale S, Perna G, Martinotti G, Di Giannantonio M, De Berardis D. The FDA "Black Box" Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits?. Frontiers in Psychiatry. 3 May 2019, 10: 294. PMC 6510161 . PMID 31130881. doi:10.3389/fpsyt.2019.00294 .
Fornaro M, Anastasia A, Valchera A, Carano A, Orsolini L, Vellante F, Rapini G, Olivieri L, Di Natale S, Perna G, Martinotti G, Di Giannantonio M, De Berardis D. The FDA "Black Box" Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits?. Frontiers in Psychiatry. 3 May 2019, 10: 294. PMC 6510161 . PMID 31130881. doi:10.3389/fpsyt.2019.00294 .
Vitiello B, Silva SG, Rohde P, Kratochvil CJ, Kennard BD, Reinecke MA, Mayes TL, Posner K, May DE, March JS. Suicidal events in the Treatment for Adolescents With Depression Study (TADS). The Journal of Clinical Psychiatry. April 2009, 70 (5): 741–747. PMC 2702701 . PMID 19552869. doi:10.4088/JCP.08m04607.
Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ. February 2005, 330 (7488): 385. PMC 549105 . PMID 15718537. doi:10.1136/bmj.330.7488.385.
Cubeddu LX. Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias. Current Cardiology Reviews. 2016, 12 (2): 141–54. PMC 4861943 . PMID 26926294. doi:10.2174/1573403X12666160301120217.
Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Canadian Pharmacists Journal. May 2016, 149 (3): 139–52. PMC 4860751 . PMID 27212965. doi:10.1177/1715163516641136.
Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, Erb JL, Churchill SE, Kohane IS, Iosifescu DV, Smoller JW, Perlis RH. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ (Clinical Research Ed.) //www.ncbi.nlm.nih.gov/pmc/articles/PMC3558546 |PMC=缺少标题 (帮助). January 2013, 346: f288. PMC 3558546 . PMID 23360890. doi:10.1136/bmj.f288 .
Hemeryck A, Belpaire F. Selective Serotonin Reuptake Inhibitors and Cytochrome P-450 Mediated Drug-Drug Interactions: An Update. Current Drug Metabolism. 2002, 3 (1): 13–37. PMID 11876575. doi:10.2174/1389200023338017.
Wong, DT, Bymaster FP, Engleman EA. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci. 1995, 57 (5): 411–41. PMID 7623609. doi:10.1016/0024-3205(95)00209-O.
Wong D, Horng J, Bymaster F, Hauser K, Molloy B. A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sci. 1974, 15 (3): 471–9. PMID 4549929. doi:10.1016/0024-3205(74)90345-2.
Jack RH, Hollis C, Coupland C, Morriss R, Knaggs RD, Butler D, Cipriani A, Cortese S, Hippisley-Cox J. Hellner C , 编. Incidence and prevalence of primary care antidepressant prescribing in children and young people in England, 1998-2017: A population-based cohort study. PLOS Medicine. July 2020, 17 (7): e1003215. PMC 7375537 . PMID 32697803. doi:10.1371/journal.pmed.1003215 .
Hughes SR, Kay P, Brown LE. Global synthesis and critical evaluation of pharmaceutical data sets collected from river systems. Environmental Science & Technology. January 2013, 47 (2): 661–77. Bibcode:2013EnST...47..661H. PMC 3636779 . PMID 23227929. doi:10.1021/es3030148.
Stewart AM, Grossman L, Nguyen M, Maximino C, Rosemberg DB, Echevarria DJ, Kalueff AV. Aquatic toxicology of fluoxetine: understanding the knowns and the unknowns. Aquatic Toxicology. November 2014, 156: 269–73. Bibcode:2014AqTox.156..269S. PMID 25245382. doi:10.1016/j.aquatox.2014.08.014.
Sumpter JP, Donnachie RL, Johnson AC. The apparently very variable potency of the anti-depressant fluoxetine. Aquatic Toxicology. June 2014, 151: 57–60. Bibcode:2014AqTox.151...57S. PMID 24411166. doi:10.1016/j.aquatox.2013.12.010 .
Brooks BW, Foran CM, Richards SM, Weston J, Turner PK, Stanley JK, Solomon KR, Slattery M, La Point TW. Aquatic ecotoxicology of fluoxetine. Toxicology Letters. Hot Spot Pollutants: Pharmaceuticals in the Environment. May 2003, 142 (3): 169–83. PMID 12691711. doi:10.1016/S0378-4274(03)00066-3.
Mennigen JA, Stroud P, Zamora JM, Moon TW, Trudeau VL. Pharmaceuticals as neuroendocrine disruptors: lessons learned from fish on Prozac. Journal of Toxicology and Environmental Health Part B: Critical Reviews. 1 July 2011, 14 (5–7): 387–412. Bibcode:2011JTEHB..14..387M. PMID 21790318. S2CID 43341257. doi:10.1080/10937404.2011.578559.
Solsona SP, Montemurro N, Chiron S, Barceló D (编). Interaction and Fate of Pharmaceuticals in Soil-Crop Systems. Handbook of Environmental Chemistry 103. Cham, Switzerland: Springer International Publishing. 2021: x+530. ISBN 978-3-030-61289-4. ISSN 1867-979X. S2CID 231746862. doi:10.1007/978-3-030-61290-0.
- • McCammon JM, Sive H. Addressing the Genetics of Human Mental Health Disorders in Model Organisms. Annual Review of Genomics and Human Genetics (Annual Reviews). 2015, 16 (1): 173–197. PMID 26002061. S2CID 19597664. doi:10.1146/annurev-genom-090314-050048.
- - • Mangoni AA, Tuccinardi T, Collina S, Vanden Eynde JJ, Muñoz-Torrero D, Karaman R, Siciliano C, de Sousa ME, Prokai-Tatrai K, Rautio J, Guillou C, Gütschow M, Galdiero S, Liu H, Agrofoglio LA, Sabatier JM, Hulme C, Kokotos G, You Q, Gomes PA. Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-3. Molecules. June 2018, 23 (7): 1596. PMC 6099979 . PMID 29966350. S2CID 49644934. doi:10.3390/molecules23071596 .
  - Echeverri N, Govendir M. Does the selective serotonin reuptake inhibitor (SSRI) fluoxetine modify canine anxiety related behaviour?. Veterinary Evidence. 2022-11-23, 7 (4). ISSN 2396-9776. S2CID 253873416. doi:10.18849/ve.v7i4.585 .
  - Sargisson RJ. Canine separation anxiety: strategies for treatment and management. Veterinary Medicine: Research and Reports. 2014-10-30, 5: 143–151. PMC 7521022 . PMID 33062616. doi:10.2147/VMRR.S60424 .
  drugs.com
  - Fluoxetine Hydrochloride. The American Society of Health-System Pharmacists. [2015-10-02]. （原始内容存档于2015-12-08）.
  - Fluoxetine Pregnancy and Breastfeeding Warnings. [2 December 2015]. （原始内容存档于2017-07-03）.
  - Fluoxetine and ibuprofen Drug Interactions. Drugs.com. [2017-03-03]. （原始内容存档于2017-08-31）.
  exlibrisgroup.com
  unisa.alma.exlibrisgroup.com
  - De Vries C, Gadzhanova S, Sykes MJ, Ward M, Roughead E. A Systematic Review and Meta-Analysis Considering the Risk for Congenital Heart Defects of Antidepressant Classes and Individual Antidepressants. Drug Safety. March 2021, 44 (3): 291–312 [2025-05-08]. PMID 33354752. S2CID 229357583. doi:10.1007/s40264-020-01027-x. （原始内容存档于2023-03-07）.
  express-scripts.com
  - Patent Expiration Dates for Common Brand-Name Drugs. [2007-07-20]. （原始内容存档于2007-09-28）.
  faa.gov
  - Duquette A, Dorr L. FAA Proposes New Policy on Antidepressants for Pilots (新闻稿). Washington, DC: Federal Aviation Administration, U.S. Department of Transportation. 2 April 2010 [2012-02-10]. （原始内容存档于14 January 2012）.
  - Office of Aerospace Medicine; Federal Aviation Administration. Decision Considerations – Aerospace Medical Dispositions: Item 47. Psychiatric Conditions – Use of Antidepressant Medications. Guide for Aviation Medical Examiners. Washington, DC: United States Department of Transportation. 2016-12-02. （原始内容存档于2017-05-03）.
  fda.gov
  fda.gov
  - Levenson M, Holland C. Antidepressants and Suicidality in Adults: Statistical Evaluation. (Presentation at Psychopharmacologic Drugs Advisory Committee; 2006-12-13). Food and Drug Administration. [2007-05-13]. （原始内容存档于27 September 2007）.
  - Stone MB, Jones ML. Clinical Review: Relationship Between Antidepressant Drugs and Suicidality in Adults (PDF). Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC). U.S. Food and Drug Administration (FDA): 11–74. 2006-11-17 [2007-09-22]. （原始内容 (PDF)存档于2007-03-16）.
  - Levenson M, Holland C. Statistical Evaluation of Suicidality in Adults Treated with Antidepressants (PDF). Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC). U.S. Food and Drug Administration (FDA): 75–140. 2006-11-17 [2007-09-22]. （原始内容 (PDF)存档于16 March 2007）.
  - Suicidality in Children and Adolescents Being Treated With Antidepressant Medications. U.S. Food and Drug Administration (FDA). 2018-11-03 [2025-05-08]. （原始内容存档于2020-08-23）.
  accessdata.fda.gov
  - FDA/Center for Drug Evaluation and Research. Prozac Label (PDF). [2025-01-04]. （原始内容存档 (PDF)于2023-01-06）.
  - Electronic Orange Book. Food and Drug Administration. April 2007 [2007-05-24]. （原始内容存档于2007-08-20）.
  google.ca
  books.google.ca
  - Myers, Richard L. The 100 most important chemical compounds : a reference guide 1. publ. Westport, Conn.: Greenwood Press. 2007: 128 [2017-01-27]. ISBN 9780313337581. （原始内容存档于2017-08-31）.
  harvard.edu
  ui.adsabs.harvard.edu
  - Hughes SR, Kay P, Brown LE. Global synthesis and critical evaluation of pharmaceutical data sets collected from river systems. Environmental Science & Technology. January 2013, 47 (2): 661–77. Bibcode:2013EnST...47..661H. PMC 3636779 . PMID 23227929. doi:10.1021/es3030148.
  - Stewart AM, Grossman L, Nguyen M, Maximino C, Rosemberg DB, Echevarria DJ, Kalueff AV. Aquatic toxicology of fluoxetine: understanding the knowns and the unknowns. Aquatic Toxicology. November 2014, 156: 269–73. Bibcode:2014AqTox.156..269S. PMID 25245382. doi:10.1016/j.aquatox.2014.08.014.
  - Sumpter JP, Donnachie RL, Johnson AC. The apparently very variable potency of the anti-depressant fluoxetine. Aquatic Toxicology. June 2014, 151: 57–60. Bibcode:2014AqTox.151...57S. PMID 24411166. doi:10.1016/j.aquatox.2013.12.010 .
  - Mennigen JA, Stroud P, Zamora JM, Moon TW, Trudeau VL. Pharmaceuticals as neuroendocrine disruptors: lessons learned from fish on Prozac. Journal of Toxicology and Environmental Health Part B: Critical Reviews. 1 July 2011, 14 (5–7): 387–412. Bibcode:2011JTEHB..14..387M. PMID 21790318. S2CID 43341257. doi:10.1080/10937404.2011.578559.
  health.harvard.edu
  - Treating social anxiety disorder. Harvard Health Publishing. [2019-05-15]. （原始内容存档于2020-09-23）.
  in.gov.br
  - Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control]. Diário Oficial da União. 2023-03-31 (2023-04-04) [2023-08-16]. （原始内容存档于2023-08-03）（巴西葡萄牙语）.
  indystar.com
  www2.indystar.com
  - Swiatek, Jeff, Prozac's profitable run coming to an end for Lilly, The Indianapolis Star, August 2, 2001, （原始内容存档于2007年8月18日）
  lilly.com
  pi.lilly.com
  - 存档副本 (PDF). [2012-02-13]. （原始内容存档 (PDF)于2016-03-03）.
  lillychina.com
  - 禮來公司. 產品介紹——百優解. [2008-07-11]. （原始内容存档于2008-07-05）.
  mhra.gov.uk
  - Committee on Safety of Medicines Expert Working Group. Report on The Safety of Selective Serotonin Reuptake Inhibitor Antidepressants (PDF). Medicines and Healthcare products Regulatory Agency (MHRA). December 2004 [2007-09-25]. （原始内容存档 (PDF)于2008-02-28）.
  modernmedicine.com
  drugtopics.modernmedicine.com
  - Verispan. Top 200 Generic Drugs by Units in 2010 (PDF). Drug Topics. （原始内容 (PDF)存档于2012-12-15）.
  msh.org
  erc.msh.org
  - Fluoxetine. International Drug Price Indicator Guide. [2015-12-02]. ^{[永久失效連結]}
  nih.gov
  ncbi.nlm.nih.gov
  - Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clinical Pharmacokinetics. March 1994, 26 (3): 201–14. PMID 8194283. S2CID 1406955. doi:10.2165/00003088-199426030-00004.
  - Husted DS, Shapira NA, Murphy TK, Mann GD, Ward HE, Goodman WK. Effect of comorbid tics on a clinically meaningful response to 8-week open-label trial of fluoxetine in obsessive compulsive disorder. Journal of Psychiatric Research. 2007, 41 (3–4): 332–337. PMID 16860338. doi:10.1016/j.jpsychires.2006.05.007.
  - Williams K, Brignell A, Randall M, Silove N, Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). The Cochrane Database of Systematic Reviews. August 2013, 8 (8): CD004677. PMC 11990048 . PMID 23959778. doi:10.1002/14651858.CD004677.pub3.
  - Myers SM. The status of pharmacotherapy for autism spectrum disorders. Expert Opinion on Pharmacotherapy. August 2007, 8 (11): 1579–1603. PMID 17685878. S2CID 24674542. doi:10.1517/14656566.8.11.1579.
  - Doyle CA, McDougle CJ. Pharmacotherapy to control behavioral symptoms in children with autism. Expert Opinion on Pharmacotherapy. August 2012, 13 (11): 1615–1629. PMID 22550944. S2CID 32144885. doi:10.1517/14656566.2012.674110.
  - Benvenuto A, Battan B, Porfirio MC, Curatolo P. Pharmacotherapy of autism spectrum disorders. Brain & Development. February 2013, 35 (2): 119–127. PMID 22541665. S2CID 19614718. doi:10.1016/j.braindev.2012.03.015.
  - Mahdi M, Hermán L, Réthelyi JM, Bálint BL. Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19. International Journal of Molecular Sciences. March 2022, 23 (7): 3812. PMC 8998734 . PMID 35409171. doi:10.3390/ijms23073812 .
  - Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JP, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JP, Geddes JR. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. April 2018, 391 (10128): 1357–1366. PMC 5889788 . PMID 29477251. doi:10.1016/S0140-6736(17)32802-7.
  - Magni LR, Purgato M, Gastaldon C, Papola D, Furukawa TA, Cipriani A, Barbui C. Fluoxetine versus other types of pharmacotherapy for depression. The Cochrane Database of Systematic Reviews. July 2013, 2013 (7): CD004185. PMC 11513554 . PMID 24353997. doi:10.1002/14651858.CD004185.pub3.
  - Etain B, Bonnet-Perrin E. [Value of fluoxetine in obsessive-compulsive disorder in the adult: review of the literature]. L'Encephale. May–Jun 2001, 27 (3): 280–289 [2025-05-08]. PMID 11488259. （原始内容存档于2025-02-02）.
  - Boaden K, Tomlinson A, Cortese S, Cipriani A. Antidepressants in Children and Adolescents: Meta-Review of Efficacy, Tolerability and Suicidality in Acute Treatment. Frontiers in Psychiatry. 2 September 2020, 11: 717. PMC 7493620 . PMID 32982805. doi:10.3389/fpsyt.2020.00717 .
  - Correll CU, Cortese S, Croatto G, Monaco F, Krinitski D, Arrondo G, Ostinelli EG, Zangani C, Fornaro M, Estradé A, Fusar-Poli P, Carvalho AF, Solmi M. Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. World Psychiatry. June 2021, 20 (2): 244–275. PMC 8129843 . PMID 34002501. doi:10.1002/wps.20881.
  - Aigner M, Treasure J, Kaye W, Kasper S. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders (PDF). The World Journal of Biological Psychiatry. September 2011, 12 (6): 400–43. PMID 21961502. S2CID 16733060. doi:10.3109/15622975.2011.602720. （原始内容存档 (PDF)于2014-08-01）.
  - Rapkin AJ, Lewis EI. Treatment of premenstrual dysphoric disorder. Women's Health. November 2013, 9 (6): 537–56. PMID 24161307. doi:10.2217/whe.13.62 .
  - Carr RR, Ensom MH. Fluoxetine in the treatment of premenstrual dysphoric disorder. The Annals of Pharmacotherapy. April 2002, 36 (4): 713–7. PMID 11918525. S2CID 37088388. doi:10.1345/aph.1A265.
  - Romano S, Judge R, Dillon J, Shuler C, Sundell K. The role of fluoxetine in the treatment of premenstrual dysphoric disorder. Clinical Therapeutics. April 1999, 21 (4): 615–33; discussion 613. PMID 10363729. doi:10.1016/S0149-2918(00)88315-0.
  - Pearlstein T, Yonkers KA. Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder. Expert Opinion on Pharmacotherapy. July 2002, 3 (7): 979–91. PMID 12083997. S2CID 9455962. doi:10.1517/14656566.3.7.979.
  - Cohen LS, Miner C, Brown EW, Freeman E, Halbreich U, Sundell K, McCray S. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstetrics and Gynecology. September 2002, 100 (3): 435–44. PMID 12220761. S2CID 753100. doi:10.1016/S0029-7844(02)02166-X.
  - Coccaro EF, Lee RJ, Kavoussi RJ. A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder. The Journal of Clinical Psychiatry. April 2009, 70 (5): 653–62. PMID 19389333. doi:10.4088/JCP.08m04150.
  - Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Archives of General Psychiatry. December 1997, 54 (12): 1081–8. PMID 9400343. doi:10.1001/archpsyc.1997.01830240035005.
  - George DT, Phillips MJ, Lifshitz M, Lionetti TA, Spero DE, Ghassemzedeh N, Doty L, Umhau JC, Rawlings RR. Fluoxetine treatment of alcoholic perpetrators of domestic violence: a 12-week, double-blind, randomized, placebo-controlled intervention study. The Journal of Clinical Psychiatry. January 2011, 72 (1): 60–5. PMC 3026856 . PMID 20673556. doi:10.4088/JCP.09m05256gry.
  - Serralde-Zúñiga AE, Gonzalez Garay AG, Rodríguez-Carmona Y, Melendez G. Fluoxetine for adults who are overweight or obese. The Cochrane Database of Systematic Reviews. October 2019, 10 (10): CD011688. PMC 6792438 . PMID 31613390. doi:10.1002/14651858.CD011688.pub2. 已忽略未知参数|collaboration= (帮助)
  - Taurines R, Gerlach M, Warnke A, Thome J, Wewetzer C. Pharmacotherapy in depressed children and adolescents. The World Journal of Biological Psychiatry. September 2011, 12 (Suppl 1): 11–5. PMID 21905988. S2CID 18186328. doi:10.3109/15622975.2011.600295.
  - Cohen D. Should the use of selective serotonin reuptake inhibitors in child and adolescent depression be banned?. Psychotherapy and Psychosomatics. 2007, 76 (1): 5–14. PMID 17170559. S2CID 1112192. doi:10.1159/000096360.
  - Rowe T. Drugs in Pregnancy. Journal of Obstetrics and Gynaecology Canada. June 2015, 37 (6): 489–92. PMID 26334601. doi:10.1016/S1701-2163(15)30222-X .
  - Clark MS, Jansen K, Bresnahan M. Clinical inquiry: How do antidepressants affect sexual function?. The Journal of Family Practice. November 2013, 62 (11): 660–1. PMID 24288712.
  - Bhat V, Kennedy SH. Recognition and management of antidepressant discontinuation syndrome. Journal of Psychiatry & Neuroscience. June 2017, 42 (4): E7–E8. PMC 5487275 . PMID 28639936. doi:10.1503/jpn.170022.
  - Warner CH, Bobo W, Warner C, Reid S, Rachal J. Antidepressant discontinuation syndrome. American Family Physician. August 2006, 74 (3): 449–56. PMID 16913164.
  - Gabriel M, Sharma V. Antidepressant discontinuation syndrome. CMAJ. May 2017, 189 (21): E747. PMC 5449237 . PMID 28554948. doi:10.1503/cmaj.160991.
  - Sørensen A, Juhl Jørgensen K, Munkholm K. Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review. Therapeutic Advances in Psychopharmacology. 2022, 12: 20451253211067656. PMID 35173954. doi:10.1177/20451253211067656.
  - Ross LE, Grigoriadis S, Mamisashvili L, Vonderporten EH, Roerecke M, Rehm J, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry. April 2013, 70 (4): 436–43. PMID 23446732. doi:10.1001/jamapsychiatry.2013.684 .
  - Lattimore KA, Donn SM, Kaciroti N, Kemper AR, Neal CR, Vazquez DM. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. Journal of Perinatology. September 2005, 25 (9): 595–604. PMID 16015372. S2CID 5558834. doi:10.1038/sj.jp.7211352.
  - Gao SY, Wu QJ, Sun C, Zhang TN, Shen ZQ, Liu CX, Gong TT, Xu X, Ji C, Huang DH, Chang Q, Zhao YH. Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births. BMC Medicine. November 2018, 16 (1): 205. PMC 6231277 . PMID 30415641. doi:10.1186/s12916-018-1193-5 .
  - De Vries C, Gadzhanova S, Sykes MJ, Ward M, Roughead E. A Systematic Review and Meta-Analysis Considering the Risk for Congenital Heart Defects of Antidepressant Classes and Individual Antidepressants. Drug Safety. March 2021, 44 (3): 291–312 [2025-05-08]. PMID 33354752. S2CID 229357583. doi:10.1007/s40264-020-01027-x. （原始内容存档于2023-03-07）.
  - Gao SY, Wu QJ, Zhang TN, Shen ZQ, Liu CX, Xu X, Ji C, Zhao YH. Fluoxetine and congenital malformations: a systematic review and meta-analysis of cohort studies. British Journal of Clinical Pharmacology. October 2017, 83 (10): 2134–2147. PMC 5595931 . PMID 28513059. doi:10.1111/bcp.13321.
  - Leslie LK, Newman TB, Chesney PJ, Perrin JM. The Food and Drug Administration's deliberations on antidepressant use in pediatric patients. Pediatrics. July 2005, 116 (1): 195–204. PMC 1550709 . PMID 15995053. doi:10.1542/peds.2005-0074.
  - Fornaro M, Anastasia A, Valchera A, Carano A, Orsolini L, Vellante F, Rapini G, Olivieri L, Di Natale S, Perna G, Martinotti G, Di Giannantonio M, De Berardis D. The FDA "Black Box" Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits?. Frontiers in Psychiatry. 3 May 2019, 10: 294. PMC 6510161 . PMID 31130881. doi:10.3389/fpsyt.2019.00294 .
  - Fornaro M, Anastasia A, Valchera A, Carano A, Orsolini L, Vellante F, Rapini G, Olivieri L, Di Natale S, Perna G, Martinotti G, Di Giannantonio M, De Berardis D. The FDA "Black Box" Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits?. Frontiers in Psychiatry. 3 May 2019, 10: 294. PMC 6510161 . PMID 31130881. doi:10.3389/fpsyt.2019.00294 .
  - Vitiello B, Silva SG, Rohde P, Kratochvil CJ, Kennard BD, Reinecke MA, Mayes TL, Posner K, May DE, March JS. Suicidal events in the Treatment for Adolescents With Depression Study (TADS). The Journal of Clinical Psychiatry. April 2009, 70 (5): 741–747. PMC 2702701 . PMID 19552869. doi:10.4088/JCP.08m04607.
  - Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ. February 2005, 330 (7488): 385. PMC 549105 . PMID 15718537. doi:10.1136/bmj.330.7488.385.
  - Cubeddu LX. Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias. Current Cardiology Reviews. 2016, 12 (2): 141–54. PMC 4861943 . PMID 26926294. doi:10.2174/1573403X12666160301120217.
  - Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Canadian Pharmacists Journal. May 2016, 149 (3): 139–52. PMC 4860751 . PMID 27212965. doi:10.1177/1715163516641136.
  - Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, Erb JL, Churchill SE, Kohane IS, Iosifescu DV, Smoller JW, Perlis RH. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ (Clinical Research Ed.) //www.ncbi.nlm.nih.gov/pmc/articles/PMC3558546 |PMC=缺少标题 (帮助). January 2013, 346: f288. PMC 3558546 . PMID 23360890. doi:10.1136/bmj.f288 .
  - Gury C, Cousin F. [Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability]. L'Encéphale. September 1999, 25 (5): 470–6. PMID 10598311.
  - Gury C, Cousin F. [Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability]. L'Encéphale. September 1999, 25 (5): 470–6. PMID 10598311.
  - Hemeryck A, Belpaire F. Selective Serotonin Reuptake Inhibitors and Cytochrome P-450 Mediated Drug-Drug Interactions: An Update. Current Drug Metabolism. 2002, 3 (1): 13–37. PMID 11876575. doi:10.2174/1389200023338017.
  - Wong, DT, Bymaster FP, Engleman EA. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci. 1995, 57 (5): 411–41. PMID 7623609. doi:10.1016/0024-3205(95)00209-O.
  - Wong D, Horng J, Bymaster F, Hauser K, Molloy B. A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sci. 1974, 15 (3): 471–9. PMID 4549929. doi:10.1016/0024-3205(74)90345-2.
  - Jack RH, Hollis C, Coupland C, Morriss R, Knaggs RD, Butler D, Cipriani A, Cortese S, Hippisley-Cox J. Hellner C , 编. Incidence and prevalence of primary care antidepressant prescribing in children and young people in England, 1998-2017: A population-based cohort study. PLOS Medicine. July 2020, 17 (7): e1003215. PMC 7375537 . PMID 32697803. doi:10.1371/journal.pmed.1003215 .
  - Hughes SR, Kay P, Brown LE. Global synthesis and critical evaluation of pharmaceutical data sets collected from river systems. Environmental Science & Technology. January 2013, 47 (2): 661–77. Bibcode:2013EnST...47..661H. PMC 3636779 . PMID 23227929. doi:10.1021/es3030148.
  - Stewart AM, Grossman L, Nguyen M, Maximino C, Rosemberg DB, Echevarria DJ, Kalueff AV. Aquatic toxicology of fluoxetine: understanding the knowns and the unknowns. Aquatic Toxicology. November 2014, 156: 269–73. Bibcode:2014AqTox.156..269S. PMID 25245382. doi:10.1016/j.aquatox.2014.08.014.
  - Sumpter JP, Donnachie RL, Johnson AC. The apparently very variable potency of the anti-depressant fluoxetine. Aquatic Toxicology. June 2014, 151: 57–60. Bibcode:2014AqTox.151...57S. PMID 24411166. doi:10.1016/j.aquatox.2013.12.010 .
  - Brooks BW, Foran CM, Richards SM, Weston J, Turner PK, Stanley JK, Solomon KR, Slattery M, La Point TW. Aquatic ecotoxicology of fluoxetine. Toxicology Letters. Hot Spot Pollutants: Pharmaceuticals in the Environment. May 2003, 142 (3): 169–83. PMID 12691711. doi:10.1016/S0378-4274(03)00066-3.
  - Mennigen JA, Stroud P, Zamora JM, Moon TW, Trudeau VL. Pharmaceuticals as neuroendocrine disruptors: lessons learned from fish on Prozac. Journal of Toxicology and Environmental Health Part B: Critical Reviews. 1 July 2011, 14 (5–7): 387–412. Bibcode:2011JTEHB..14..387M. PMID 21790318. S2CID 43341257. doi:10.1080/10937404.2011.578559.
  - • McCammon JM, Sive H. Addressing the Genetics of Human Mental Health Disorders in Model Organisms. Annual Review of Genomics and Human Genetics (Annual Reviews). 2015, 16 (1): 173–197. PMID 26002061. S2CID 19597664. doi:10.1146/annurev-genom-090314-050048.
    
    • Mangoni AA, Tuccinardi T, Collina S, Vanden Eynde JJ, Muñoz-Torrero D, Karaman R, Siciliano C, de Sousa ME, Prokai-Tatrai K, Rautio J, Guillou C, Gütschow M, Galdiero S, Liu H, Agrofoglio LA, Sabatier JM, Hulme C, Kokotos G, You Q, Gomes PA. Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-3. Molecules. June 2018, 23 (7): 1596. PMC 6099979 . PMID 29966350. S2CID 49644934. doi:10.3390/molecules23071596 .
    Sargisson RJ. Canine separation anxiety: strategies for treatment and management. Veterinary Medicine: Research and Reports. 2014-10-30, 5: 143–151. PMC 7521022 . PMID 33062616. doi:10.2147/VMRR.S60424 .
    dailymed.nlm.nih.gov
    Prozac- fluoxetine hydrochloride capsule. DailyMed. 2021-12-23 [2023-03-11]. （原始内容存档于2024-09-26）.
    Sarafem (fluoxetine hydrochloride tablets ) for oral use Initial U.S. Approval: 1987. DailyMed. [12 March 2023].
    Symbyax- olanzapine and fluoxetine hydrochloride capsule. DailyMed. 2020-04-21 [2020-09-30]. （原始内容存档于2025-05-02）.
    nimh.nih.gov
    NIMH•Eating Disorders. The National Institute of Mental Health. National Institute of Health. 2011 [2013-11-25]. （原始内容存档于2011-08-19）.
    pubmed.ncbi.nlm.nih.gov
    Etain B, Bonnet-Perrin E. [Value of fluoxetine in obsessive-compulsive disorder in the adult: review of the literature]. L'Encephale. May–Jun 2001, 27 (3): 280–289 [2025-05-08]. PMID 11488259. （原始内容存档于2025-02-02）.
    pubchem.ncbi.nlm.nih.gov
    Fluoxetine. PubChem. U.S. National Library of Medicine. [2015-03-13]. （原始内容存档于2015-04-02）.
    ntp.niehs.nih.gov
    Hines RN, Adams J, Buck GM, Faber W, Holson JF, Jacobson SW, Keszler M, McMartin K, Segraves RT, Singer LT, Sipes IG, Williams PL. NTP-CERHR Expert panel report on the reproductive and developmental toxicity of fluoxetine （页面存档备份，存于互联网档案馆）. NIH Publication No. 05-4471. 2004;1-211.
    nihr.ac.uk
    evidence.nihr.ac.uk
    Antidepressants for children and teenagers: what works for anxiety and depression?. NIHR Evidence (Plain English summary) (National Institute for Health and Care Research). 3 November 2022 [2025-05-08]. S2CID 253347210. doi:10.3310/nihrevidence_53342. （原始内容存档于2022-11-05）.
    plosjournals.org
    medicine.plosjournals.org
    David Healy, Andrew Herxheimer, and David B. Menkes. Antidepressants and Violence: Problems at the Interface of Medicine and Law. PLoS Med. 2006, (3(9): e372) [2020-09-12]. doi:10.1371/journal.pmed.0030372. （原始内容存档于2009-03-20）.
    popsci.com
    Combining certain opioids and commonly prescribed antidepressants may increase the risk of overdose. www.Popsci.com. 2022-07-30 [2022-07-30].
    psychcentral.com
    Grohol, J. FDA Approves Symbyax for Treatment Resistant Depression. Psych Central Blog. [2010-07-17]. （原始内容存档于2017-12-26）.
    semanticscholar.org
    api.semanticscholar.org
    Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clinical Pharmacokinetics. March 1994, 26 (3): 201–14. PMID 8194283. S2CID 1406955. doi:10.2165/00003088-199426030-00004.
    Myers SM. The status of pharmacotherapy for autism spectrum disorders. Expert Opinion on Pharmacotherapy. August 2007, 8 (11): 1579–1603. PMID 17685878. S2CID 24674542. doi:10.1517/14656566.8.11.1579.
    Doyle CA, McDougle CJ. Pharmacotherapy to control behavioral symptoms in children with autism. Expert Opinion on Pharmacotherapy. August 2012, 13 (11): 1615–1629. PMID 22550944. S2CID 32144885. doi:10.1517/14656566.2012.674110.
    Benvenuto A, Battan B, Porfirio MC, Curatolo P. Pharmacotherapy of autism spectrum disorders. Brain & Development. February 2013, 35 (2): 119–127. PMID 22541665. S2CID 19614718. doi:10.1016/j.braindev.2012.03.015.
    Antidepressants for children and teenagers: what works for anxiety and depression?. NIHR Evidence (Plain English summary) (National Institute for Health and Care Research). 3 November 2022 [2025-05-08]. S2CID 253347210. doi:10.3310/nihrevidence_53342. （原始内容存档于2022-11-05）.
    Aigner M, Treasure J, Kaye W, Kasper S. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders (PDF). The World Journal of Biological Psychiatry. September 2011, 12 (6): 400–43. PMID 21961502. S2CID 16733060. doi:10.3109/15622975.2011.602720. （原始内容存档 (PDF)于2014-08-01）.
    Carr RR, Ensom MH. Fluoxetine in the treatment of premenstrual dysphoric disorder. The Annals of Pharmacotherapy. April 2002, 36 (4): 713–7. PMID 11918525. S2CID 37088388. doi:10.1345/aph.1A265.
    Pearlstein T, Yonkers KA. Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder. Expert Opinion on Pharmacotherapy. July 2002, 3 (7): 979–91. PMID 12083997. S2CID 9455962. doi:10.1517/14656566.3.7.979.
    Cohen LS, Miner C, Brown EW, Freeman E, Halbreich U, Sundell K, McCray S. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstetrics and Gynecology. September 2002, 100 (3): 435–44. PMID 12220761. S2CID 753100. doi:10.1016/S0029-7844(02)02166-X.
    Taurines R, Gerlach M, Warnke A, Thome J, Wewetzer C. Pharmacotherapy in depressed children and adolescents. The World Journal of Biological Psychiatry. September 2011, 12 (Suppl 1): 11–5. PMID 21905988. S2CID 18186328. doi:10.3109/15622975.2011.600295.
    Cohen D. Should the use of selective serotonin reuptake inhibitors in child and adolescent depression be banned?. Psychotherapy and Psychosomatics. 2007, 76 (1): 5–14. PMID 17170559. S2CID 1112192. doi:10.1159/000096360.
    Lattimore KA, Donn SM, Kaciroti N, Kemper AR, Neal CR, Vazquez DM. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. Journal of Perinatology. September 2005, 25 (9): 595–604. PMID 16015372. S2CID 5558834. doi:10.1038/sj.jp.7211352.
    De Vries C, Gadzhanova S, Sykes MJ, Ward M, Roughead E. A Systematic Review and Meta-Analysis Considering the Risk for Congenital Heart Defects of Antidepressant Classes and Individual Antidepressants. Drug Safety. March 2021, 44 (3): 291–312 [2025-05-08]. PMID 33354752. S2CID 229357583. doi:10.1007/s40264-020-01027-x. （原始内容存档于2023-03-07）.
    Mennigen JA, Stroud P, Zamora JM, Moon TW, Trudeau VL. Pharmaceuticals as neuroendocrine disruptors: lessons learned from fish on Prozac. Journal of Toxicology and Environmental Health Part B: Critical Reviews. 1 July 2011, 14 (5–7): 387–412. Bibcode:2011JTEHB..14..387M. PMID 21790318. S2CID 43341257. doi:10.1080/10937404.2011.578559.
    Solsona SP, Montemurro N, Chiron S, Barceló D (编). Interaction and Fate of Pharmaceuticals in Soil-Crop Systems. Handbook of Environmental Chemistry 103. Cham, Switzerland: Springer International Publishing. 2021: x+530. ISBN 978-3-030-61289-4. ISSN 1867-979X. S2CID 231746862. doi:10.1007/978-3-030-61290-0.
    
    • McCammon JM, Sive H. Addressing the Genetics of Human Mental Health Disorders in Model Organisms. Annual Review of Genomics and Human Genetics (Annual Reviews). 2015, 16 (1): 173–197. PMID 26002061. S2CID 19597664. doi:10.1146/annurev-genom-090314-050048.
    
    • Mangoni AA, Tuccinardi T, Collina S, Vanden Eynde JJ, Muñoz-Torrero D, Karaman R, Siciliano C, de Sousa ME, Prokai-Tatrai K, Rautio J, Guillou C, Gütschow M, Galdiero S, Liu H, Agrofoglio LA, Sabatier JM, Hulme C, Kokotos G, You Q, Gomes PA. Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-3. Molecules. June 2018, 23 (7): 1596. PMC 6099979 . PMID 29966350. S2CID 49644934. doi:10.3390/molecules23071596 .
    Echeverri N, Govendir M. Does the selective serotonin reuptake inhibitor (SSRI) fluoxetine modify canine anxiety related behaviour?. Veterinary Evidence. 2022-11-23, 7 (4). ISSN 2396-9776. S2CID 253873416. doi:10.18849/ve.v7i4.585 .
    tga.gov.au
    tga.gov.au
    Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017. Therapeutic Goods Administration (TGA). 2022-06-21 [2024-03-30]. （原始内容存档于2023-07-06）.
    ebs.tga.gov.au
    Prozac Fluoxetine Hydrochloride (PDF). TGA eBusiness Services. Eli Lilly Australia Pty. Limited. 2013-10-09 [2013-11-23]. （原始内容存档于2017-04-25）.
    uptodate.com
    UpToDate. uptodate.com. [2022-08-10]. （原始内容存档于2022-08-09）.
    veterinaryevidence.org
    Echeverri N, Govendir M. Does the selective serotonin reuptake inhibitor (SSRI) fluoxetine modify canine anxiety related behaviour?. Veterinary Evidence. 2022-11-23, 7 (4). ISSN 2396-9776. S2CID 253873416. doi:10.18849/ve.v7i4.585 .
    washingtonpost.com
    MacPherson M. Prozac, Prejudice and the Politics of Depression. The Washington Post. 1990-09-02 [2018-04-23]. （原始内容存档于2021-09-03）.
    web.archive.org
    Fluoxetine Hydrochloride. The American Society of Health-System Pharmacists. [2015-10-02]. （原始内容存档于2015-12-08）.
    Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017. Therapeutic Goods Administration (TGA). 2022-06-21 [2024-03-30]. （原始内容存档于2023-07-06）.
    Mental health. Health Canada. 9 May 2018 [2024-04-13]. （原始内容存档于2024-09-21）.
    Prozac- fluoxetine hydrochloride capsule. DailyMed. 2021-12-23 [2023-03-11]. （原始内容存档于2024-09-26）.
    Prozac Fluoxetine Hydrochloride (PDF). TGA eBusiness Services. Eli Lilly Australia Pty. Limited. 2013-10-09 [2013-11-23]. （原始内容存档于2017-04-25）.
    Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control]. Diário Oficial da União. 2023-03-31 (2023-04-04) [2023-08-16]. （原始内容存档于2023-08-03）（巴西葡萄牙语）.
    禮來公司. 產品介紹——百優解. [2008-07-11]. （原始内容存档于2008-07-05）.
    FDA/Center for Drug Evaluation and Research. Prozac Label (PDF). [2025-01-04]. （原始内容存档 (PDF)于2023-01-06）.
    Fluoxetine Pregnancy and Breastfeeding Warnings. [2 December 2015]. （原始内容存档于2017-07-03）.
    Myers, Richard L. The 100 most important chemical compounds : a reference guide 1. publ. Westport, Conn.: Greenwood Press. 2007: 128 [2017-01-27]. ISBN 9780313337581. （原始内容存档于2017-08-31）.
    WHO Model List of Essential Medicines (PDF). World Health Organization. October 2013 [2014-04-22]. （原始内容存档 (PDF)于2014-04-23）.
    Verispan. Top 200 Generic Drugs by Units in 2010 (PDF). Drug Topics. （原始内容 (PDF)存档于2012-12-15）.
    Symbyax- olanzapine and fluoxetine hydrochloride capsule. DailyMed. 2020-04-21 [2020-09-30]. （原始内容存档于2025-05-02）.
    Grohol, J. FDA Approves Symbyax for Treatment Resistant Depression. Psych Central Blog. [2010-07-17]. （原始内容存档于2017-12-26）.
    Forman-Hoffman V, Middleton JC, Feltner C, Gaynes BN, Weber RP, Bann C, Viswanathan M, Lohr KN, Baker C, Green J. Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update (报告). Comparative Effectiveness Review. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ). 2018-05-17 [2024-02-12]. doi:10.23970/ahrqepccer207. （原始内容存档于2018-07-10）. |issue=被忽略 (帮助)
    NIMH•Eating Disorders. The National Institute of Mental Health. National Institute of Health. 2011 [2013-11-25]. （原始内容存档于2011-08-19）.
    Treating social anxiety disorder. Harvard Health Publishing. [2019-05-15]. （原始内容存档于2020-09-23）.
    Etain B, Bonnet-Perrin E. [Value of fluoxetine in obsessive-compulsive disorder in the adult: review of the literature]. L'Encephale. May–Jun 2001, 27 (3): 280–289 [2025-05-08]. PMID 11488259. （原始内容存档于2025-02-02）.
    Antidepressants for children and teenagers: what works for anxiety and depression?. NIHR Evidence (Plain English summary) (National Institute for Health and Care Research). 3 November 2022 [2025-05-08]. S2CID 253347210. doi:10.3310/nihrevidence_53342. （原始内容存档于2022-11-05）.
    Aigner M, Treasure J, Kaye W, Kasper S. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders (PDF). The World Journal of Biological Psychiatry. September 2011, 12 (6): 400–43. PMID 21961502. S2CID 16733060. doi:10.3109/15622975.2011.602720. （原始内容存档 (PDF)于2014-08-01）.
    David Healy, Andrew Herxheimer, and David B. Menkes. Antidepressants and Violence: Problems at the Interface of Medicine and Law. PLoS Med. 2006, (3(9): e372) [2020-09-12]. doi:10.1371/journal.pmed.0030372. （原始内容存档于2009-03-20）.
    De Vries C, Gadzhanova S, Sykes MJ, Ward M, Roughead E. A Systematic Review and Meta-Analysis Considering the Risk for Congenital Heart Defects of Antidepressant Classes and Individual Antidepressants. Drug Safety. March 2021, 44 (3): 291–312 [2025-05-08]. PMID 33354752. S2CID 229357583. doi:10.1007/s40264-020-01027-x. （原始内容存档于2023-03-07）.
    Levenson M, Holland C. Antidepressants and Suicidality in Adults: Statistical Evaluation. (Presentation at Psychopharmacologic Drugs Advisory Committee; 2006-12-13). Food and Drug Administration. [2007-05-13]. （原始内容存档于27 September 2007）.
    Stone MB, Jones ML. Clinical Review: Relationship Between Antidepressant Drugs and Suicidality in Adults (PDF). Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC). U.S. Food and Drug Administration (FDA): 11–74. 2006-11-17 [2007-09-22]. （原始内容 (PDF)存档于2007-03-16）.
    Levenson M, Holland C. Statistical Evaluation of Suicidality in Adults Treated with Antidepressants (PDF). Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC). U.S. Food and Drug Administration (FDA): 75–140. 2006-11-17 [2007-09-22]. （原始内容 (PDF)存档于16 March 2007）.
    Suicidality in Children and Adolescents Being Treated With Antidepressant Medications. U.S. Food and Drug Administration (FDA). 2018-11-03 [2025-05-08]. （原始内容存档于2020-08-23）.
    Committee on Safety of Medicines Expert Working Group. Report on The Safety of Selective Serotonin Reuptake Inhibitor Antidepressants (PDF). Medicines and Healthcare products Regulatory Agency (MHRA). December 2004 [2007-09-25]. （原始内容存档 (PDF)于2008-02-28）.
    Fluoxetine. PubChem. U.S. National Library of Medicine. [2015-03-13]. （原始内容存档于2015-04-02）.
    Fluoxetine and ibuprofen Drug Interactions. Drugs.com. [2017-03-03]. （原始内容存档于2017-08-31）.
    UpToDate. uptodate.com. [2022-08-10]. （原始内容存档于2022-08-09）.
    Hines RN, Adams J, Buck GM, Faber W, Holson JF, Jacobson SW, Keszler M, McMartin K, Segraves RT, Singer LT, Sipes IG, Williams PL. NTP-CERHR Expert panel report on the reproductive and developmental toxicity of fluoxetine （页面存档备份，存于互联网档案馆）. NIH Publication No. 05-4471. 2004;1-211.
    Can you get high on fluoxetine?. [2011-08-29]. （原始内容存档于2011-11-23）（英语）.
    存档副本 (PDF). [2012-02-13]. （原始内容存档 (PDF)于2016-03-03）.
    Swiatek, Jeff, Prozac's profitable run coming to an end for Lilly, The Indianapolis Star, August 2, 2001, （原始内容存档于2007年8月18日）
    Electronic Orange Book. Food and Drug Administration. April 2007 [2007-05-24]. （原始内容存档于2007-08-20）.
    Patent Expiration Dates for Common Brand-Name Drugs. [2007-07-20]. （原始内容存档于2007-09-28）.
    Macnair P. BBC – Health: Prozac. BBC. September 2012. （原始内容存档于2012-12-11）. In 2011 over 43 million prescriptions for antidepressants were handed out in the UK and about 14 percent (or nearly 6 million prescriptions) of these were for a drug called fluoxetine, better known as Prozac.
    Duquette A, Dorr L. FAA Proposes New Policy on Antidepressants for Pilots (新闻稿). Washington, DC: Federal Aviation Administration, U.S. Department of Transportation. 2 April 2010 [2012-02-10]. （原始内容存档于14 January 2012）.
    Office of Aerospace Medicine; Federal Aviation Administration. Decision Considerations – Aerospace Medical Dispositions: Item 47. Psychiatric Conditions – Use of Antidepressant Medications. Guide for Aviation Medical Examiners. Washington, DC: United States Department of Transportation. 2016-12-02. （原始内容存档于2017-05-03）.
    Class 1/2 Certification – Depression (PDF). Civil Aviation Authority. [2021-07-21]. （原始内容 (PDF)存档于2021-10-10）.
    wfsbp.org
    Aigner M, Treasure J, Kaye W, Kasper S. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders (PDF). The World Journal of Biological Psychiatry. September 2011, 12 (6): 400–43. PMID 21961502. S2CID 16733060. doi:10.3109/15622975.2011.602720. （原始内容存档 (PDF)于2014-08-01）.
    who.int
    apps.who.int
    WHO Model List of Essential Medicines (PDF). World Health Organization. October 2013 [2014-04-22]. （原始内容存档 (PDF)于2014-04-23）.
    worldcat.org
    Solsona SP, Montemurro N, Chiron S, Barceló D (编). Interaction and Fate of Pharmaceuticals in Soil-Crop Systems. Handbook of Environmental Chemistry 103. Cham, Switzerland: Springer International Publishing. 2021: x+530. ISBN 978-3-030-61289-4. ISSN 1867-979X. S2CID 231746862. doi:10.1007/978-3-030-61290-0.
    Echeverri N, Govendir M. Does the selective serotonin reuptake inhibitor (SSRI) fluoxetine modify canine anxiety related behaviour?. Veterinary Evidence. 2022-11-23, 7 (4). ISSN 2396-9776. S2CID 253873416. doi:10.18849/ve.v7i4.585 .
    
    2020-2023
    CC BY-SA 4.0
    Terms of use
    
    BestRef.net (ver. 1.02)
    
    BestRef shows popularity and reliability scores for sources in references of Wikipedia articles in different languages. Data extraction based on complex method using Wikimedia dumps. To find the most popular and reliable sources we used information about over 300 million references of Wikipedia articles. More details...
    
    Usefull links
    
    Wikipedia Wikidata DBpedia
    
    Go to top
    
    In Wikipedia verifiability we trust

氟西汀 (Chinese Wikipedia)

ahrq.gov

effectivehealthcare.ahrq.gov

answers.com

wiki.answers.com

archive.org

archive.today

bbc.co.uk

books.google.com

caa.co.uk

canada.ca

doi.org

drugs.com

exlibrisgroup.com

unisa.alma.exlibrisgroup.com

express-scripts.com

faa.gov

fda.gov

fda.gov

accessdata.fda.gov

google.ca

books.google.ca

harvard.edu

ui.adsabs.harvard.edu

health.harvard.edu

in.gov.br

indystar.com

www2.indystar.com

lilly.com

pi.lilly.com

lillychina.com

mhra.gov.uk

modernmedicine.com

drugtopics.modernmedicine.com

msh.org

erc.msh.org

nih.gov

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

nimh.nih.gov

pubmed.ncbi.nlm.nih.gov

pubchem.ncbi.nlm.nih.gov

ntp.niehs.nih.gov

nihr.ac.uk

evidence.nihr.ac.uk

plosjournals.org

medicine.plosjournals.org

popsci.com

psychcentral.com

semanticscholar.org

api.semanticscholar.org

tga.gov.au

tga.gov.au

ebs.tga.gov.au

uptodate.com

veterinaryevidence.org

washingtonpost.com

web.archive.org

wfsbp.org

who.int

apps.who.int

worldcat.org